Catalyst Calendar

Thu, May 21, 2026

1 updates

7:00 AM

PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program

BOSTON --(BUSINESS WIRE)--May 21, 2026-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its

Presentation / AbstractIDMC-15 poster presentation Wed, May 27, 2026, 10:45 AM EDTpepgen.com

Tue, May 12, 2026

1 updates

PEPG

4:05 PM

PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

– FREEDOM2-DM1 5 mg/kg cohort demonstrated favorable safety, splicing and vHOT data, with the totality of results supporting the potential of the ongoing 10 mg/kg dose cohort – – The FREEDOM2 10 mg/kg cohort is fully enrolled, with data on track for 2H 2026 – – Well-funded with $132.3M of cash as

Enrollment • Phase 2Enrollment milestone Tue, Mar 31, 2026pepgen.com